卡托普利对实验性病毒性心肌炎心肌胶原增生的干预作用

Effect of captopril on myocardial collagen hyperplasia in mice with viral myocarditis

探讨卡托普利对实验性病毒性心肌炎心肌胶原增生的干预作用。雄性Balb c小鼠随机分为对照组、柯萨奇B3病毒感染组 (感染组 )和病毒感染加卡托普利治疗组 (治疗组 )。苦味酸天狼猩红胶原特异染色 ,半定量分析胶原面积及胶原平均光密度。第 14天和 30天实验结果 :(1)感染组小鼠存活率分别为 4 5 5 %、38 5 % ,治疗组分别为72 7%、6 1 5 % ;(2 )心肌胶原面积前者分别为 1 6 5± 0 14、3 0 2± 0 2 9,后者分别为 1 4 9± 0 13、1 75± 0 18;(3)心肌胶原平均光密度前者分别为 0 4 3± 0 0 2、0 5 7± 0 0 5 ,后者分别为 0 4 1± 0 0 2、0 4 5± 0 0 5。提示在病毒性心肌炎急性期予以卡托普利治疗能抑制慢性期心肌胶原纤维过度增生 。

To observe the effect of captopril on myocardial collagen hyperplasia in mice with viral myocarditis. Male Balb/c mice were randomly divided into three groups: control group,coxsackie B 3 virus(CVB 3) infection group(Infection group), CVB 3 infection with captopril treatment group(Treatment group). Picrosirius red staining was used to investigate myocardial collagen expression. Collagen area as well as average optical density (AOD) were semiquantitatively analysed. The results on day 14 and 30 showed that: (1)The survival rates of the infection group were 45.5% and 38.5% respectively and in treatment group were 72.7% and 61.5% respectively. (2)The myocardial collagen area of the infection group were 1.65±0.14 and 3.02±0.29, the treatment group were 1.49±0.13 and 1.75±0.18. (3)The AODs of the infection group were 0.43±0.02 and 0.57±0.05 respectively, the treatment group were 0.41±0.02 and 0.45±0.05 respectively. It is suggested that captopril inhibits myocardial collagen excessive hyperplasia in the chronic stage and benefits prognosis of viral myocarditis.